Quality of Life in SMA Patients Under Treatment With Nusinersen

Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Mix, Lucas, Winter, Benedikt, Wurster, Claudia D., Platen, Sophia, Witzel, Simon, Uzelac, Zeljko, Graf, Heiko, Ludolph, Albert C., Lulé, Dorothée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039289/
https://www.ncbi.nlm.nih.gov/pubmed/33854472
http://dx.doi.org/10.3389/fneur.2021.626787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039289/
https://www.ncbi.nlm.nih.gov/pubmed/33854472
http://dx.doi.org/10.3389/fneur.2021.626787

Ejemplares similares